Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based op­tion

Bris­tol My­ers Squibb may be trail­ing Mer­ck and Roche in the check­point race to treat front­line cas­es of non-small cell lung can­cer, but as it does, it makes sure to bring its best feet for­ward.

Just days af­ter scor­ing a land­mark NSCLC ap­proval for Op­di­vo and Yer­voy alone for PD-L1 pos­i­tive pa­tients, the com­pa­ny said the FDA has al­so OK’d us­ing the two agents with a lim­it­ed course of chemo re­gard­less of the bio­mark­er sta­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER